Dose of XARELTO for Switching From Another Anticoagulant During Initial DVT or PE Treatment
Aspirin and an oral anticoagulant – can they be used together? - NPS MedicineWise
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials -
Updated Guidelines on Outpatient Anticoagulation | AAFP
Care Transitions in Anticoagulation Management for Patients With Atrial Fibrillation: An Emphasis on Safety | Ochsner Journal
Xarelto® - Responsible Use
Transition of Anticoagulants 2014
Effectiveness and Safety of Standard- and Low-Dose Rivaroxaban in Asians With Atrial Fibrillation - ScienceDirect
Antithrombotic Management of Venous Thromboembolism: JACC Focus Seminar - ScienceDirect
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons | The BMJ
Direct Oral Anticoagulants: A User's Guide | Consultant360
Transitioning Between Anticoagulants Continuous Infusion Unfractionated Heparin (UFH) SC LMWH or Fondaparinux Rivaroxaban (Xarel
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons | The BMJ
Cureus | Clinical Outcomes and Costs of Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Inpatients: A Cross-Sectional Study
![PDF] Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c3bd71fdf61b8f8bdc9321c5d380254016ae03ea/20-Table1-1.png "PDF] Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery | Semantic Scholar")
PDF] Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery | Semantic Scholar
How to switch from rivaroxaban to LMWH? | Download Scientific Diagram
Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week - ScienceDirect
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial - The Lancet
Recommendations for Switching to and From Rivaroxaban 9 | Download Table
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism | Thrombosis Journal | Full Text
Apixaban starting dose after 1 week LMWH therapy (PE or DVT)? | ResearchGate
Rivaroxaban: a fully-subsidised oral anticoagulant
Guidance on converting between anticoagulants
Treatment Considerations | XARELTO® (rivaroxaban) HCP
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges | Journal of the American Heart Association
Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology | Revista Española de Cardiología
New Oral Anticoagulants: A Review - ppt video online download
Time for a change? Switching anticoagulants in patients with AF or VTE | Thrombosis Adviser
